side view of scientist looking into microscope in bright research lab

Life Sciences & Healthcare

Belgium

With over 150 international specialist lawyers across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your lifesciences business. We work with and have established long-term relationships with the top 100 lifesciences companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. As members and partners of major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EFPIA and EUCOMED we help shape the legal frameworks impacting the lifesciences sector. 

We regularly advise our clients on their day-to-day operational needs such as, patent enforcement, commercial and clinical trial agreements, protection of privacy and trade secrets, e-health, support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement as well as regulatory advice. 

Equally, when you need lifesciences specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

Read more Read less
Lifes­ci­ences & Health­care
15/12/2015
CMS Glob­al Lifes­ci­ences For­um 2015
Shap­ing the fu­ture through in­nov­a­tion and col­lab­or­a­tion

Feed

Show only
Tom Heremans
30/11/2018
Novem­ber 2018 News­let­ter
05/12/2018
Im­port­ant leg­al changes in Bel­gi­um's health­care sec­tor
A new law was ad­op­ted on 30 Oc­to­ber 2018 con­tain­ing vari­ous pro­vi­sions on health. This law con­tains amend­ments to dif­fer­ent reg­u­la­tions in the health­care sec­tor. Some of the main changes are as fol­lows. Vari­ous as­pects of the law of 7 May 2017 on clin­ic­al tri­als.
November 2018
NGOS CAN ASK THE COM­MIS­SION TO RE­VIEW ITS DE­CISION...
BIO-SCI­ENCE LAW RE­VIEW - VOL 16 IS­SUE 6 BSLR : CASE...
24/08/2018
Gov­ern­ment Is­sues Brexit Tech­nic­al No­tice for Life Sci­ences
On 23 Au­gust 2018, the UK Gov­ern­ment (the "Gov­ern­ment") is­sued the first wave of its tech­nic­al pa­pers de­signed to provide guid­ance to com­pan­ies to help pre­pare for a "No Deal" Brexit. In this scen­ario, there will be no "trans­ition peri­od" but rather the UK.
Laurine Georgis
16/03/2018
March 2018 News­let­ter
18/05/2018
EU Product Li­ab­il­ity Dir­ect­ive still an ad­equate tool, ac­cord­ing to...
On 7 May 2018, the European Com­mis­sion pub­lished its fifth re­port on the per­form­ance of the EU Product Li­ab­il­ity Dir­ect­ive (Dir­ect­ive/85/374/EEC) in the mem­ber states. The dir­ect­ive in­tro­duced the concept of strict li­ab­il­ity for pro­du­cers of de­fect­ive products.
31/01/2018
Janu­ary 2018 News­let­ter
17/04/2018
NGOs can ask the Com­mis­sion to re­view its de­cision on ge­net­ic­ally...
The Gen­er­al Court de­cided in its de­cision of 14 March 2018 that non-gov­ern­ment­al or­gan­iz­a­tions (“NGOs”) can ask the Com­mis­sion to re­view its de­cision on au­thor­iz­ing the pla­cing on the mar­ket of ge­net­ic­ally mod­i­fied food and feed.
30/11/2017
Novem­ber 2017 News­let­ter
31/01/2018
New law fur­ther sup­ports cheap­er pre­scrip­tion drugs
Par­lia­ment ad­op­ted a new law on 25 Decem­ber 2017, which has as one of its ob­ject­ives the pro­mo­tion of the pre­scrip­tion of cheap­er drugs. Pre­scrip­tion drugs are clas­si­fied by price: they can be “cheap medi­cines” or “cheapest medi­cines”, based on dif­fer­ent cri­ter­ia.
28/06/2017
June 2017 News­let­ter
25/01/2018
European Com­mis­sion as­sesses ad­equacy of Gen­er­al Food Law in food...
In an eval­u­ation of the EU le­gis­lat­ive frame­work for the 2002 Gen­er­al Food Law Reg­u­la­tion (GFLR), the European Com­mis­sion has found that this frame­work ap­pears to ad­dress most cur­rent trends, such as growth, com­pet­it­ive­ness and in­creased glob­al­isa­tion, but.